The evolution of coreceptor tropism in HIV-infected patients interrupting suppressive antiretroviral therapy

Clinical Infectious Diseases

Volumn 52, Issue 5, 2011, Pages 671-673

  Waters, Laura J ^a   Scourfield, Andrew T ^a   Marcano, Marie ^a   Gazzard, Brian G ^a   Bower, Mark ^a   Nelson, Mark ^a   Stebbing, Justin ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5 ANTAGONIST; VIRUS RNA;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; DRUG TOLERABILITY; FEMALE; GENE SWITCHING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MOLECULAR EVOLUTION; PHENOTYPE; PRIORITY JOURNAL; VIRAL GENETICS; VIRAL TROPISM; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV; HIV FUSION INHIBITORS; HIV INFECTIONS; HUMANS; MALE; PREGNANCY; VIRAL TROPISM; WITHHOLDING TREATMENT;

EID: 79951835509     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciq198     Document Type: Article

References (13)

1. Davidson I, Beardsell H, Smith B, et al. The frequency and reasons for antiretroviral switching with specific antiretroviral associations: the SWITCH study. Antiviral Res 2010;86:227-9.
2. Saag M, Ive P, Heera J, et al. A multicenter, randomized, double-blind, comparative trial of a novel CCR5 antagonist, maraviroc versus efavirenz, both in combination with Combivir (zidovudine/lamivudine), for the treatment of antiretroviral-naive subjects infected with R5 HIV 1: week 48 results of the MERIT study. In: Program and abstracts of the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. Sydney, Australia: 2007. Abstract WESS104.
3. Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008;359:1429-41.
4. Vandekerckhove LPR, Wensing AMJ, Kaiser R, et al. Consensus statement of the European guidelines on clinical management of HIV-1 tropism testing. Tenth International Congress on Drug Therapy in HIV Infection, November 7-11, 2010. Glasgow. Abstract O12.
5. Geretti AM, Mackie N. Determining HIV-1 tropism in routine clinical practice; December 2009, Available at: http://www.bhiva.org/Tropism.aspx. Accessed 12 November 2010.
6. Soulie C, Marcelin AG, Ghosn J, et al. HIV-1 X4/R5 co-receptor in viral reservoir during suppressive HAART. AIDS 2007;21:2243-5. (Pubitemid 350287224)
7. Cooper V, Gellaitry G, Hankins M, Fisher M, Horne R. The influence of symptom experiences and attributions on adherence to highly active anti-retroviral therapy (HAART): a six-month prospective, follow-up study. AIDS Care 2009;21:520-8.
8. Streinu-Cercel A, de Gorgolas M, Müller M, et al. Switching from a toxicity-causing antiretroviral to enfuvirtide in patients with HIV: the SWITCH TOX study. HIV Clin Trials 2008;9:375-86.
9. Sax PE. Report from the 2008 joint ICAAC/IDSA meeting. Maraviroc vs. efavirenz: a reanalysis of MERIT. AIDS Clin Care 2008;20:98-104.
10. Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008;359:1429-41.
11. Lewden C, Chene G, Morlat P, et al. HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr 2007;46:72-7. (Pubitemid 47514615)
12. McGovern R, Thielen A, Mo T, et al. Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies. AIDS 2010;24:2517-25.
13. McGovern R, Dong W, Zhong X, et al. Population-based sequencing of the V3-loop is comparable to the enhanced sensitivity Trofile assay (ESTA) in predicting virologic response to maraviroc (MVC) of treatment-naive patients in the MERIT trial. In: Program and abstracts of the 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA: 2010. Abstract 92.